Related Experiment Videos
Prednisolone-induced changes in dystrophic skeletal muscle
Ivan Fisher1, David Abraham, Khaled Bouri
1Muscle Cell Biology Group, MRC Clinical Sciences Centre, Imperial College, London, UK.
Summary
Glucocorticoids benefit Duchenne muscular dystrophy (DMD) by altering muscle fiber type, not by regeneration or reducing inflammation. This study reveals complex gene expression changes in treated mdx mice, indicating a shift towards normal muscle characteristics.
Area of Science:
- Molecular Biology
- Genetics
- Muscle Physiology
Background:
- Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease.
- Glucocorticoids are used to delay DMD progression, but their mechanism is unclear.
Purpose of the Study:
- To investigate the molecular mechanisms by which glucocorticoids impact skeletal muscle in mdx mice, an animal model for DMD.
Main Methods:
- Comparison of skeletal muscle gene expression profiles between prednisolone-treated mdx mice and control mice at early (1 week) and late (6 weeks) time points.
- Analysis of differentially expressed genes, including those related to metabolism, proteolysis, and calcium signaling.
- Assessment of muscle regeneration, macrophage infiltration, utrophin expression, and muscle fiber type distribution.
Main Results:
- Early and late differential gene expression was observed, with specific genes like FKBP51, kallikreins, and potassium channel regulators showing altered expression.
- Treatment did not improve muscle regeneration, reduce macrophage infiltration, or change utrophin levels.
- A significant decrease in slow muscle fibers was noted in treated mdx soleus muscles after 6 weeks.
Conclusions:
- Glucocorticoid treatment in DMD models involves complex gene expression changes.
- The therapeutic benefit appears to stem from a shift in muscle fiber type towards a more normal composition, rather than direct regeneration or anti-inflammatory effects.